Entering text into the input field will update the search result below

Ultragenyx on go with U.S. marketing application for UX007 for mid-2019; shares up 3%

Nov. 14, 2018 9:43 AM ETUltragenyx Pharmaceutical Inc. (RARE) StockBy: Douglas W. House, SA News Editor
  • Ultragenyx (NASDAQ:RARE +3.1%) announces that it plans to file a U.S. marketing application by mid-2019 seeking approval for UX007 for the treatment of patients with long-chain fatty acid oxidation disorders. The application will be supported with Phase 2 data.
  • UX007 is a purified pharmaceutical-grade form of a triglyceride compound called triheptanoin that provides patients with medium-length odd-chain fatty acids which increase the intermediate substrates in the Krebs cycle, a key energy-generating process, which produces new glucose.
  • Previously: Ultragenyx up 3% premarket on FDA sign-off early filing of NDA for UX007 (Aug. 29)

Recommended For You

More Trending News

About RARE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RARE--
Ultragenyx Pharmaceutical Inc.